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A B S T R A C T
Background
Shortening the duration of radiation therapy would benefit women with early breast cancer treated with breast conservation. It may
also improve access to radiation therapy by improving efficiency in radiation oncology departments globally. This can only happen if
the shorter treatment is as effective and safe as conventional radiation therapy.
Objectives
To assess the effects of altered fraction size on women with early breast cancer who have undergone breast conserving surgery.
Search strategy
We searched theCochrane Breast Cancer Group Specialised Register (June 2006), MEDLINE (November 2006), EMBASE (November
2006), reference lists for articles, and relevant conference proceedings. No language constraints were applied.
Selection criteria
Randomised controlled trials of unconventional versus conventional fractionation inwomenwith early breast cancer who had undergone
breast conserving surgery.
Data collection and analysis
Data extraction was performed independently by the authors with disagreements resolved by discussion. Missing data was sought by
contacting the authors concerned.
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Main results
Two trials were included and reported on 2644 women. The women were highly selected with node negative tumours smaller than 5
cm and negative pathological margins; 46% of the women had a cup separation size of less than 25 cm. The studies were of high quality.
Data for local recurrence and breast appearance were not available in a form which could be combined. Unconventional fractionation
(delivering radiation therapy in larger amounts each day but over fewer days than with conventional fractionation) did not appear to
affect: (1) local-recurrence free survival (absolute difference 0.4%, 95% CI -1.5% to 2.4%), (2) breast appearance (risk ratio (RR) 1.01,
95% CI 0.88 to 1.17; P = 0.86), (3) survival at five years (RR 0.97, 95% CI 0.78 to 1.19; P = 0.75), (4) late skin toxicity at five years
(RR 0.99, 95% CI 0.44 to 2.22; P = 0.98, or (5) late radiation toxicity in sub-cutaneous tissue (RR 1.0, 95% CI 0.78 to 1.28; P =
0.99).
Authors’ conclusions
We have evidence from two high quality randomised trials that the use of unconventional fractionation regimes (greater than 2 Gy per
fraction) does not affect breast appearance or toxicity and does not seem to affect local recurrence for selected women treated with breast
conserving therapy. These are women with node negative tumours smaller than 5 cm and negative pathological margins. Two new trials
have been published in March 2008. Their results are consistent with our findings. The results of these trials will be incorporated in
the next update of this review.
P L A I N L A N G U A G E S U M M A R Y
Fraction size in radiation treatment for breast conservation in early breast cancer
Using fewer radiation treatments for women with early breast cancer who wish to preserve their breast achieves similar outcomes in
breast appearance and survival. In addition, cancer control in the breast appears to be similar. Breast cancer is an important disease for
women, with one in eight women in the United States and Australia and one in nine women in the United Kingdon being diagnosed
with the condition. Breast conserving therapy (removing the tumour but keeping an intact breast) has proven to be as effective as
mastectomy (removing the breast tissue) in terms of survival for women with cancer confined to the breast, with or without evidence
of cancer in the local lymph nodes, as long as a five to six week course of radiation therapy is delivered. This involves 25 to 30 daily
visits to a radiation oncology department. Without radiation therapy after breast conserving surgery there is a high risk of breast cancer
returning in the breast (local recurrence), in as many as 30 to 40 women per 100. This means that for every local recurrence avoided
with radiation, one death is avoided at 15 years. Many women prefer breast conservation so that the demand for radiation services
has increased. Giving fewer radiation treatments (fractions) would be beneficial to women where this has the same effect on tumour
control and survival without poorer cosmetic outcomes. To reduce the number of treatments the radiation dose delivered per fraction
is increased. This may also reduce demand on radiation resources and be more convenient for women.
Two trials were included in this review and involved 2644 women. Breast appearance was not significantly different for women
undergoing fewer treatments. Survival was not altered by having fewer treatments and there was no significant difference in late skin
toxicity or radiation toxicity. The available information for local control, that is when the tumour does not recur in the treated breast,
could not be combined but was similar in each trial. Most of the women in the trials (98.4%) had tumours less than 5 cm and complete
removal of the tumour on pathology; 91% had no evidence of cancer in their lymph nodes. This review indicates that for women who
fit these criteria, using fewer radiation treatments after tumour removal could be considered.
B A C K G R O U N D
Description of the condition
Breast cancer is the most common cancer occurring in women.
The lifetime risk of being diagnosed with breast cancer for women
living in Australia and the United States is one in eight, and one
in nine for women living in the United Kingdom (AIHW 2006;
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ONS 1999; Ries 2004). Breast cancer is the second most common
cause of cancer death in females.
A significant change has occurred in the management of women
with early breast cancer (cancer confined to the breast and nearby
lymph nodes) over the last three decades. Previously most women
with early breast cancer underwent removal of the whole breast
(mastectomy). Evidence from several randomised controlled tri-
als (Fisher 1989; Veronesi 1990) and a meta-analysis of 36 tri-
als (EBCTCG 1995) confirms that long-term overall survival is
equivalent using breast conserving treatment compared with mas-
tectomy. Breast conserving treatment comprises removal of the
portion of the breast containing the tumour followed by radiation
treatment to the remaining breast tissue.Other studies have shown
that quality of life is enhanced in women who undergo breast
conserving treatment (Al-Ghazal 2000). Consequently, breast
conserving treatment has become the recommended option for
womenwith early breast cancer inmanywestern countries (NBCC
2001; NIH 1991). Breast conserving surgery now accounts for
70% of breast cancer operations in some series (Chouillet 1994)
and, as a result, demand for radiation treatment services has in-
creased. Some health services have struggled to meet this increas-
ing demand because of a shortage of trained personnel and expen-
sive radiation treatment machines (Ash 2000; Mackillop 1994).
Description of the intervention
Radiation following breast conserving surgery involves treatment
to the cancer site with ionising radiation. Typically the radiation
is delivered over a period of 5 to 6 weeks using a standard 2 Gy
(Gray) radiation dose per fraction, in 25 to 30 treatment episodes,
to a total dose of 50 to 60 Gy.
Recently there has been interest from cancer service providers in
shortening the overall treatment time. One method of achieving
this is to increase the size of each fraction thereby decreasing the
total number of fractions required. For example, case series using
40 Gy in 15 fractions or 36 Gy in 12 fractions have been reported
(Ash 2000; Olivotto 1996). Shorter fractionation schedules have
the advantages of using machine and staff time more efficiently
and reducing patient inconvenience.
Concerns have been raised, however, as to whether shorter frac-
tionation schedules have equivalent outcomes in terms of local tu-
mour control, breast appearance (cosmesis), overall survival, and
patient satisfaction. The concern with larger fraction sizes is based
on radiobiological principles which state that the fraction size is
the dominant factor in determining late side effects. The aim of
conventional fractionation at 2 Gy per fraction is to decrease the
rate of late tissue damage whilst aiming to maximise tumour con-
trol with acceptable acute toxicity (Hall 1994). Higher fraction
size could lead to increased scarring and retraction of breast tissue
as well as skin atrophy (thinning) and telangiectasia (dilated blood
vessels).
Why it is important to do this review
The optimal fractionation schedule is notwell established (Whelan
1993) but evidence from clinical trials suggests that the results of
shorter schedules may be equivalent with respect to local control
and cosmesis (Whelan 2000; Yarnold 1994). Published trials to
date have been too small to reliably detect differences in cancer
recurrence rates.
If a shorter fractionation schedule can be established as providing
equivalent outcomes for women this could lead to more efficient
use of radiation services andmore expedient treatment for patients.
O B J E C T I V E S
To determine the effect of altered radiation fraction size on out-
comes for women with early breast cancer who have undergone
breast conserving surgery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials were considered for inclusion.
The comparisons were required to be unconfounded, that is the
treatment given to the intervention and comparator groups could
differ only in relation to the fractionation scheme used. Trials
where the participants received adjuvant treatment in the form of
chemotherapy,monoclonal antibody treatment, or hormonal ther-
apy were eligible providing these treatments were applied equally
to all study groups. Published and unpublished studies were eligi-
ble.
Types of participants
Women with histologically confirmed early breast cancer who had
undergone breast conserving surgery. Early breast cancer is de-
fined as invasive adenocarcinoma restricted to the breast, plus or
minus the local lymph nodes, which can be removed surgically
(EBCTCG 2002), that is T1-2, N0-1, M0 (Fleming 1997).
Surgery could include lumpectomy, wide local excision, quadran-
tectomy, or segmental resection; with or without axillary dissec-
tion, node sampling, or sentinel node biopsy.
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Types of interventions
Postoperative radiation to the breast alone and delivered using con-
ventional fractionation (1.8 to 2 Gy per fraction) versus postoper-
ative radiation to the breast alone at greater than 2Gy per fraction.
In order to compare the differing dose schedules we converted
fractionation schemes to biologically equivalent doses (BED). The
dose prescribed and the prescription point had to be clearly iden-
tified. We specified the dose in accordance with the International
Commission on Radiation Units and Measurements (ICRU 50)
recommendations with respect to dose, dose specification point,
and dose per fraction. Where possible, we converted data found
in studies into this form.
Types of outcome measures
Primary outcomes
1. Local recurrence in the ipsilateral breast (i.e. the same breast
where the cancer had been diagnosed)
2. Appearance or cosmesis (objective and subjective) of the post-
treatment breast
Secondary outcomes
1. Overall survival (time fromdate of randomisation to death from
any cause, or number of deaths from any cause)
2. Toxicity (including acute and late effects of radiation therapy
and chemotherapy-related toxicity; individual protocol-based def-
initions were used
3. Cancer-specific mortality
4. Relapse-free survival
5. Mastectomy rate (following local recurrence)
6. Quality of life (trial-specific instruments)
7. Costs (to women and health services)
Search methods for identification of studies
The Cochrane Breast Cancer Group Specialised Register was
searched (June 2006). The details of search strategies used
by the Group for the identification of studies and the pro-
cedure used to code references are outlined in their mod-
ule (http://www.mrw.interscience.wiley.com/cochrane/clabout/
articles/BREASTCA/frame.html). Studies coded as ’early’ and ’ra-
diotherapy and dose intensity’ on the Specialised Register were
extracted for consideration.
In addition, a comprehensive search ofMEDLINE (OVID) (1966
to June 2006) (see Appendix 1) and EMBASE (OVID) (1980 to
October 2006) (see Appendix 2) was conducted.
Searches were not limited by language or date.
Data collection and analysis
Selection of studies
All four original authors checked the titles and abstracts retrieved
by the searches. The newer authors did so for the repeated search.
Each author independently assessed the full text of all studies we
thought relevant to the review with differences being resolved by
discussion.
Data extraction and management
Data extraction was performed independently by three authors
(BH, ML, and DF) with disagreements being resolved by discus-
sion. Data were entered into RevMan 4.2 for analysis. Where data
was limited, we requested further information from the authors
of the original studies.
Assessment of methodological quality of included studies
Two review authors (BH, ML) categorised the methodological
quality of each eligible study using the system outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2006). DF resolved any discrepancies which arose.
The quality of trials was assessed according to the following.
Low risk of bias: plausible bias unlikely to seriously alter results,
all of the quality criteria met.
Moderate risk of bias: plausible bias that raised some doubt about
results. One or more of the quality criteria partly met.
High risk of bias: plausible bias that seriously weakened confidence
in results. One or more of the quality criteria not met.
Specific quality measures included: adequacy of concealment of
randomisation, whether the analysis was by intention to treat,
presence of blinding, and adequacy of follow up. Because of the
nature of the interventions involved in this review, blinding of par-
ticipants and investigators was not possible although blinding of
outcome assessment was possible (for cosmesis and late toxicity).
As a result this was regarded as an important feature in our quality
assessment. We did use adequacy of follow up as a quality crite-
rion, setting an arbitrary threshold of 80% follow up as adequate.
The studies were assessed in relation to whether the methods and
procedures were adequate, inadequate, or unclear.
Sensitivity analysis was planned on the basis of study quality and
was to be performedwith andwithout trials of low quality to assess
the effect of quality on the results. This was not possible with only
two included trials.
Measures of treatment effect
Dichotomous measures were presented as risk ratios (RR) with
95% confidence intervals (CI) (Deeks 2003). Continuous vari-
ables were presented as weighted mean difference, where possi-
ble. We usedMantel-Haenszel methods to calculate pooled results
(Greenland 1985; Mantel 1959).
Data synthesis (meta-analysis)
We applied the intention-to-treat principle in analysing data from
the trials and determined a weighted average treatment effect
using the fixed-effect model to combine results (Mantel 1959)
on RevMan 4.2. Because our comparison of interest was uncon-
ventional fractionation versus conventional fractionation, when
analysing the trials we combined the two different ’fractionation
dose’ unconventional arms of the Owen 2006 trial. In the future,
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if more information becomes available then separate analysis may
be possible to investigate a dose effect for different fractionation
schedules.
Continuous variables, for example cosmesis, were dichotomised
in the reports so we reported them as RRs. For late skin toxicity,
percentages given in the text were converted to numbers and a RR
reported (as there were data from one trial only a weighted mean
difference could not be calculated).
Global cosmetic outcome (appearance) was reported for 735
women at five years (Whelan 2002) as a dichotomised out-
come. The four-point scale European Organisation for Research
and Treatment of Cancer (EORTC) Cosmetic Rating System
(Aaronson 1988) was used and the results were dichotomised as:
good or excellent versus poor or fair.
Skin toxicity (Whelan 2000) was assessed using a five-point scale
(Winchester 1992) (see Additional Table 1) and analysed as a
dichotomous outcome using RR.The results were dichotomised
into: none or mild versus moderate, marked or severe.
We assumed that induration and subcutaneous toxicity (at five
years), reported by Owen 2006 and Whelan 2002 respectively,
represented the same outcome and could, therefore, be combined
for analysis. Whelan 2002 used the TROG/EORTC five-point
late radiation morbidity scale (Winchester 1992) (see Additional
Table 1) and Owen 2006 used a four-point trial-specific scale
(see Additional Table 2). No patient in Whelan 2002 had severe
(Grade 4) toxicity. The results were dichotomised in the Owen
2006 report but reported in full in Whelan 2000. In order to
combine the results, the Whelan 2000 results were dichotomised
into two groups: those with nil or slight late radiation toxicity, and
those who had any greater toxicity; that is the women who had
scores of two or more were counted as having toxicity.
Marked or late change in breast appearance results were di-
chotomised in the report (Owen 2006).
If sufficient data become available in future updates we will use
recommended methods to collect and combine the data. We will
use the mean difference method unless trials have reported results
on different scales, in which case we will use a standardised mean
difference to summarise data (Deeks 2003).
Subgroup analysis and investigation of heterogeneity
The current version of the review does not contain any subgroup
analyses because of the lack of data. However, if sufficient data
become available in future updates we may perform subgroup
analyses to investigate whether the effects of different radiation
fraction schemes differ depending on nodal status, margin status,
hormone receptor status, and tumour stage or other factors which
may become relevant in the future.
We assessed heterogeneity both visually and statistically using the
chi-squared test (Altman 1992; Walker 1988).
Radiation doses were converted to the biological equivalent dose
(BED), where BED = nd (1+d/alpha/beta) (Fowler 1989; Steel
1997). This was to facilitate comparison of radiation doses given
at differing dose per fraction. The value of alpha/beta used for
breast tumour cells was four (Steel 1997; Thames 1987; Williams
1985). Using these values, we aimed to compare those studies with
a BED < 75 and a BED > 75. Brachytherapy (radiation sources
applied directly to the body) would be converted to BED using
the method of Stitt (Stitt 1992; Yamada 1999). For brachytherapy
we will record data, where possible, in the form of dose, dose
specification point, plane of interest (for example at 1 cm from
the central plane), mean central dose, and peripheral dose.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
A total of 2119 abstracts were screened, 61 papers in full were con-
sidered for eligibility. Two were identified as ongoing studies and
47 were excluded (see table Characteristics of excluded studies).
The 12 reports that met the inclusion criteria (Anon 1997;
OCOG 1992; Owen 1994; Owen 2006; Whelan 2000; Whe-
lan 2002; Yarnold 1992; Yarnold 1994; Yarnold 1994a; Yarnold
2001; Yarnold 2001a; Yarnold 2005) related to two separate stud-
ies (Owen 2006; Whelan 2002) . Both of the trials had published
their results at different times with different periods of follow up.
We used the most recent publication as the source for the review
supplementing this with information from earlier reports, if nec-
essary. Thus, for the Owen 2006 trial the primary source is Owen
2006, with eight other publications found for this trial (Anon
1997; Owen 1994; Yarnold 1992; Yarnold 1994; Yarnold 1994a;
Yarnold 2001; Yarnold 2001a; Yarnold 2005). The primary source
for the second trial wasWhelan 2002, with two other publications
found (OCOG 1992; Whelan 2000).
The two randomised trials included in this current version of the
review involved a total of 2644 women.
Whelan 2002 was a randomised controlled trial comparing two
different fractionation regimes (42.5 Gy in 16 fractions and 50 Gy
in 25 fractions). The trial was multicentred with patients recruited
from tertiary institutions. This study included 1234 women with
invasive breast cancer who were without nodal involvement, were
treated with lumpectomy, and had negative pathological margins.
Patients with large breasts (as defined by a cup size separation of
greater than 25 cm, that is the breast measured greater than 25 cm
left to right at its widest part) were excluded. The primary out-
come measure was local recurrence of invasive breast cancer in the
treated breast. The trial reported breast appearance and late radia-
tion toxicity but did not assess costs or quality of life. For reporting
skin toxicity, Whelan 2002 used the five-point Radiation Oncol-
ogy Group/ EORTC late radiation morbidity scale (Winchester
1992) (Additional Table 1). Global cosmetic outcome was assessed
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by trained clinical trials nurses using the four-point European Or-
ganisation for Research and Treatment of Cancer (EORTC) Cos-
metic Rating System (Additional Table 3).
More detail is available in the table Characteristics of included
trials.
The second study (Owen 2006) was a randomised controlled trial
comparing three fractionation regimens (39 Gy in 13 fractions,
42.9 Gy in 13 fractions, and 50 Gy in 25 fractions). The trial was
multicentred in a tertiary setting. The study included 1410women
with invasive breast cancer who were treated with breast conserv-
ing surgery and had negative pathological margins. The primary
outcome measure was late change in breast appearance. The trial
reported both cosmesis and late radiation toxicity but did not as-
sess costs or quality of life. Cosmesis (appearance) was assessed
in 806 women at annual follow-up visits; clinicians used a four-
point scale (Additional Table 4). We have no evidence that these
women were substantially different to the remainder of women in
the trial. These results were dichotomised in the report into fair
or poor versus good or excellent (Owen 2006).
More detail is available in the table Characteristics of included
studies.
Risk of bias in included studies
Owen 2006 and Whelan 2002 had adequate follow up. Analysis
was by intention to treat inWhelan 2002 but this was not stated in
Owen 2006. Randomisation was adequate and concealed (Owen
2006; Whelan 2002). It was not stated whether outcome assessors
were blinded to treatment allocation in Whelan 2002 but those
who assessed cosmesis in Owen 2006 were not aware which study
group the women belonged to. The results of our categorisation
are available in the Characteristics of included studies table.
Effects of interventions
Two trials enrolling 2644 women were included in the review. In
the results presented here, ratios of treatment effects are given such
that RRs < 1.0 would indicate a beneficial effect of unconventional
fractionation over conventional fractionation (although, as noted
below, most of these results were not statistically significant).
Primary outcomes
Ipsilateral local recurrence
Data were provided for this comparison but could not be readily
analysed. Owen 2006 reported local recurrence but it was reported
as number of events in each arm per person years. The data was
reported as first event data inWhelan 2002, that is events included
local recurrence, distant recurrence, and death. This meant that
not all local recurrences were reported. We have contacted the
authors for more information but unsuccessfully.
In Whelan 2002, 44 local recurrences in 1234 women were re-
ported as first event data at five years: 21 in the unconventional
arm and 23 in the conventional arm. The authors reported that
local-recurrence free survival at five years was 97.2% in the un-
conventional arm and 96.8% in the conventional arm (absolute
difference 0.4%, 95% CI -1.5 to 2.4). These figures were directly
extracted from the text (Whelan 2002); that is local recurrence
rates were 2.8% in the unconventional arm and 3.2% in the con-
ventional arm.
Owen 2006 reported 158 events in 1410 randomised women.
These were reported as number of events in each arm per person
years with a median follow up of 9.7 years and a maximum follow
up of 18.4 years (see Additional Table 5). The authors reported
that the risk of ipsilateral tumour recurrence at 10 years was 14.8%
(95%CI 11.2 to 18.3) for the 39Gy in the 13 fractions arm; 9.6%
(95% CI 6.7 to 12.6) for the 42.9 Gy in 13 fractions arm; and
12.1% (95% CI 8.8 to 15.5) for the 50 Gy in 25 fractions arm
(figures from text) (Yarnold 2005). If this is converted to incidence
ratios relative to the control group (that is 50 Gy in 25 fractions),
the incidence ratio for 42.9 Gy in 13 fractions was 0.87 (95% CI
0.56 to 1.33; P = 0.50); and for 39 Gy in 13 fractions it was 1.35
(95% CI 0.92 to 1.98; P = 0.11).
Appearance (objective and subjective) of the post-treatment
breast (cosmesis)
Data were available from both trials but not in a form which could
be combined in analysis.
Global cosmetic outcomewas reported for 735women at five years
(Whelan 2002). The triallists performed cosmetic assessment on
1220 women at baseline and had complete cosmetic data on 735
women at five years (the time of interest for the outcome).We have
no indication that these women were different to the remainder of
those randomised. A four-point scale (Aaronson 1988) was used
and the results were dichotomised as: good or excellent versus poor
or fair. These results were reported as percentages at three and five
years with the total number of women available for evaluation at
each time period; as we did not know the numbers in each arm,
we were unable to derive figures from these data. At five years,
the percentage of patients with good or excellent global cosmetic
outcome was 76.8% in the altered fractionation arm and 77.4%
in the conventional fractionation arm (absolute difference -0.6%,
95% CI -6.5% to 5.5%); figures from the text (Whelan 2002).
Owen 2006 reported breast cosmesis (median follow up of 8.1
years, maximum 15 years) using a four-point scale (see Additional
Table 4). A total of 806 women (see Description of studies) were
assessed and the results were reported as a dichotomised outcome
in the report. Of 535 women in the altered fractionation arm,
224 (41.8%) were scored as having a good or excellent result and
106 of 271 (39.1%) in the conventional fractionation arm had
good or excellent result (figures derived from the text): RR 1.07
(95% CI 0.90 to 1.28; P = 0.46). Testing for heterogeneity was
not applicable.
Secondary outcomes
1. Overall survival (time from date of randomisation to death
from any cause, or number of deaths from any cause at five years)
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The RR was 0.97 (95% CI 0.78 to 1.19; P = 0.75). There was
no heterogeneity (P = 0.79) between the trials (Comparisons and
data 01.01).
2. Toxicity (including acute and late effects of radiation therapy,
and chemotherapy-related toxicity)
Individual protocol-based definitions were used. Toxicity and late
effects were reported on assessable numbers.
Skin toxicity (Whelan 2002) was assessed using the Radiation On-
cologyGroup/ EORTC late radiationmorbidity scale (Winchester
1992), which has a five-point scale (Table 1). No woman had se-
vere (Grade 4) skin toxicity: RR 0.99 (95% CI 0.44 to 2.22; P =
0.98). A test for heterogeneity was not applicable with only one
trial.
Late radiation subcutaneous toxicity: the RR was 1.00 (95% CI
0.78 to 1.28; P = 0.99). There was no heterogeneity (P = 0.21)
between the trials ( Owen 2006;Whelan 2002) (Comparisons and
data 01.02.)
Owen 2006 reported five year follow up for any or marked change
in breast appearance and found no significant difference between
the unconventional and conventional arms for any change (RR
1.01, 95% CI 0.88 to 1.17; P = 0.86) or for marked change (RR
1.24, 95% CI 0.77 to 2.00; P = 0.37). There was no difference in
moderate or marked breast distortion between the two trial arms
(RR 1.01, 95% CI 0.87 to 1.17; P = 0.90) (Owen 2006).
Late toxicity outcomes were reported in Whelan 2002. Two
women in the unconventional arm and two in the conventional
arm developed radiation pneumonitis. One woman in the con-
ventional arm fractured a rib.
3. Cancer specific mortality
No data.
4. Relapse-free survival
No data.
5. Mastectomy rate
No data.
6. Quality of life (trial-specific instruments)
No data.
7. Costs (to women and health services)
No data.
D I S C U S S I O N
For women with early breast cancer, achieving and maintaining
local control in addition to maximising survival are the main goals
of management.Whilst conservative surgery followed by radiation
therapy allows preservation of the breast, the requirement for five
to six weeks of radiation therapy, which may only be available at
some distance from the woman’s residence, can be a burden. The
many costs involved (monetary and other) may mean that women
choose mastectomy over breast conserving therapy to avoid the
necessity for radiation therapy (Nattinger 2001).
Shortening the duration of postoperative breast radiation would
provide the advantage of shorter disruption of normal activities
and less time away from home and family. Reducing the number
of fractions required would also free up radiation therapy machine
time. This may reduce waiting lists and improve timely access to
radiation therapy for other patients with cancer. The ability to
safely reduce the number of fractions required to treat women
with early breast cancer may, therefore, result in many benefits at
a personal, national, and international level provided acceptable
local control can be maintained with this approach.
This review set out to explore whether shortened (altered fraction-
ation) regimes used to treat women who have had conservative
surgery for early breast cancer can offer the same tumour control
and cosmetic results as longer fractionation regimes.We have been
able to include data from two randomised controlled trials that
compared different fractionation schemes. The comparison stud-
ied is altered fractionation (fraction size greater than 2 Gy) versus
conventional fractionation (2 Gy per fraction).
It was not possible to combine the data because of reporting issues,
but local recurrence rates appear similar in each of the trial arms.
The reported risk of ipsilateral tumour recurrence at 10 years was
14.8% (95% CI 11.2 to 18.3) for the 39 Gy in 13 fractions arm,
9.6% (95% CI 6.7 to 12.6) for the 42.9 Gy in 13 fractions arm,
and 12.1% (95% CI 8.8 to 15.5) for the 50 Gy in 25 fractions
arm (Yarnold 2005). In Whelan 2002, local recurrence rates were
2.8% in the unconventional arm and 3.2% in the conventional
arm.
For these comparisons, there are no significant differences between
the fractionation techniques in regard to cosmesis, late skin toxi-
city, and late radiation toxicity. For overall survival, there was no
significant difference between the techniques. No data were avail-
able for costs, quality of life, or women’s preference. There are
limitations related to assessment of subjective outcomes, such as
cosmesis and breast induration, but this was well performed us-
ing standardised tools by trained observers in both trials (Owen
2006; Whelan 2002); with blinding of the outcome assessors to
the treatment allocation in Owen 2006.
Although both trials independently showed no difference in lo-
cal control with altered fractionation, the reporting did not allow
combination of data. The findings of this review provide reassur-
ance that the practice of offering shortened radiation fractiona-
tion regimes to carefully selected groups of patients is unlikely to
be detrimental in terms of breast appearance, late radiation breast
toxicity, or survival. However, there are some caveats.
(1) These results are mostly applicable to women with node neg-
ative T1-2 tumours with negative pathological margins.
A total of 92% of the women enrolled in the two trials were node
negative (all of the 1234 women in Whelan 2002, and 1187 of
1410 women enrolled in Owen 2006) and they all had negative
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pathological margins. The vast majority (2622/2644) of women
had T1-2 tumours (that is tumour size less than 5 cm). Whelan
limited the eligible women to those with a cup size separation
of 25 cm or less because, for women with larger breasts, there is
concern that altered fractionation may cause more toxicity (this
represents 46% of the total number of women included in the
analysis). Although women with T3 tumours (size greater than 5
cm) were eligible for the Owen study, they comprised 1.6% (22/
1410) of the study population and only 0.83% of the women
analysed in the review.
(2) The follow up (five years) is not adequate to detect differences
in breast cancermortality. If, however, there are truly nodifferences
in local recurrence one would not expect to see differences in
mortality.
In total, 222 local recurrences were reported in 2644 women,
but the 44 recurrences in Whelan 2002 were those presenting
as first events (a composite endpoint including local recurrence,
distant metastases, and death); so this figure may underestimate
the total number of local recurrences. The Owen trial was not
powered to detect significant differences in local recurrence. Using
an alpha/beta ratio of 4 for breast tumour cells (Fowler 1989; Steel
1987; Williams 1985) allows conversion of radiation doses to a
common biological equivalent dose (BED) (Fowler 1989; Steel
1997). When the altered fractionation regime radiation doses are
converted to BED (see Additional Table 6), it is clear that two
regimens (39 Gy in 13 fractions and 42.5 Gy in 16 fractions)
(Whelan 2002) have lower biological equivalent doses than the
conventional 50 Gy in 25 fractions.
It has not been possible at this time to answer questions of cost,
quality of life, and patient preferences within this review. There
is no information about the acute toxicity related to the differ-
ent fractionation regimens but one could reasonably expect that
shorter regimens are more readily tolerated and, therefore, would
enhance quality of life for women.
A detailed assessment of quality of life is planned for a subset of pa-
tients enrolled in the START trial (Yarnold 1999), whichmay pro-
vide more information. Little is known about patient preferences
in this setting but as rural women have consistently been shown to
have more mastectomies in comparison with women who live in
bigger centres (Nattinger 2001; Schroen 2005) it may be that they
choose mastectomy to reduce their time away from home (assum-
ing they are offered conservative treatment as frequently as women
in the city). Another trial has been identified (Wallace 1993) and
we have contacted the authors requesting further information.
(3) We do not have information about combining other thera-
pies (for example trastuzumab) with these fractionation regimes,
although observational data suggests it to be a safe practice with
conventionally fractionated radiation therapy (Romond 2005).
(4) The optimum ’dose’ of altered fractionation remains unknown.
In Owen 2006, two novel altered fractionation schedules were
tested; however, we were not able to analyse them separately to
see if one was superior to the other. In addition, new techniques,
such as accelerated partial breast irradiation, shorten treatment
time even more by using larger fraction sizes to a smaller volume
of breast tissue. These techniques are the subject of a number of
ongoing trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In selectedwomenwith early breast cancer (node negative tumours
with negative margins and size 5 cm or less) shortened fractiona-
tion regimens may be considered.
Implications for research
There are a number of questions still unanswered that relate to the
use of altered fraction size in the treatment of early breast cancer
for women undergoing breast cancer surgery. The authors know of
one pending trial (see Ongoing studies) which has been designed
to test the effects of using fraction sizes greater than 2 Gy in terms
of normal tissue responses, loco-regional tumour control, quality
of life (cohort followed for QOL), and economic consequences.
This study will be included in the next update of this review.
A trial which has completed accrual but is awaiting further follow
up and analysis was identified. The START trial (A and B) was
designed to test the effects of using fraction sizes greater than
2 Gy in terms of normal tissue responses, loco-regional tumour
control, quality of life (cohort followed for QOL), and economic
consequences. This study will be included in the next update of
this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Owen 2006
Methods Centrally randomised, multicentre setting: tertiary cancer centres
Participants 1410 women with operable (T1-3N0-1MO) invasive breast cancer requiring radiotherapy
Interventions Experimental arm (n=474): 39 Gy in 13 fractions, or 42.9 Gy in 13 fractions (n=466) over 5 weeks.
Control arm: 50 Gy in 25 fractions (n=470) over 5 weeks
Outcomes Primary outcome: late change in breast appearance (scored from photos). Secondary endpoints: palpable
breast induration (fibrosis) and ipsilateral breast recurrence. Women reviewed 3-monthly to 36 months,
6-monthly to 60 months, then annually. Annual physician toxicity review. Photographs annually to 60
months, then at 10 years in all evaluable patients
Notes Photos: frontal photos taken after surgery before RT, then annually to 5 years and at 10 years under
standard conditions. Photos scored by three observers
Low risk of bias
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - adequate
Whelan 2002
Methods Centrally randomised, multicentred, setting: tertiary institutions, intention to treat analysis, no post-
randomization exclusions
Participants 1234 women with invasive breast cancer (< 5cm, i.e. no T3/T4 lesions, negative margins and node
negative) treated with lumpectomy. Exclusions: those with multicentric disease, large breasts (separation
> 25cm) and those with bilateral breast cancer
Interventions Experimental arm (n=622): radiation dose to breast alone, 42.5 Gy in 16 fractions (2.65 Gy/#, BED=70.
65)
Control arm (n=612): radiation dose 50 Gy in 25 fractions (dose per fraction 2.0 Gy, BED=75)
Outcomes Primary outcome: local recurrence of invasive breast cancer in treated breast
Secondary outcomes: distant recurrence of invasive breast cancer, death, breast cosmesis and late radiation
toxicity. Cosmesis assessed using EORTC Cosmetic Rating System (trained nurse). Global cosmetic
outcome assessed using 4-point scale.
Late radiation toxicity assessed by trained nurse using RTOG/EORTC late radiation morbidity scale
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Whelan 2002 (Continued)
Notes Concurrent interventions were evenly divided between the 2 arms: 254 women in the experimental arm
received tamoxifen and 251 in the control arm, 66 women in the experimental arm received chemotherapy
and 66 in the control arm. Moderate risk of bias
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - adequate
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Angelakis 1973 Not RCT
Anon 1981 Surgery was wide local excision versus mastectomy
Anon 1982 Not RCT
Anon 1999 Not RCT
Ash 1995 Not RCT
Asrari 1999 Not RCT
Baglan 2001 Did not examine external beam radiation
Baillet 1990 Did not examine 2 Gy versus > 2 Gy per fraction
Bartelink 1998 Not RCT
Bates 1975 Surgery was modified radical mastectomy
Bates 1988 Surgery was modified radical mastectomy
Bedwinik 1990 Not RCT
Brinkley 1984 Surgery was modified radical mastectomy
Bruce 1971 Surgery was modified radical mastectomy versus simple mastectomy
Di Biase 2002 Not RCT
Dvivedi 1978 Surgery was modified radical mastectomy and regional radiation therapy was examined
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(Continued)
EBCTG 2000 Not RCT
Fentiman 1991 Not RCT
Formenti 2002 Partial breast radiation therapy was examined
Goel 2002 Surgery was modified radical mastectomy
Gorodetsky 1999 Not RCT
Kovarik 1995 Not RCT
Liljegren 1993 Intervention was radiation therapy in experimental arm only
Mladenovic 2001 Not RCT
Moody 1994 Refers to women randomised in Owen 2006, but only patients randomised from 1986 to 1991
Moonen 1994 Not RCT
Nyman 1994 Not RCT
Nyman 1995 Not RCT
Olivotto 1996 Intervention was +/- aspirin
Ortholan 2003 Not RCT
Poortmans 2001 Not RCT
Ptaszynski 1999 Examined boost versus no boost
Rodger 1998 Not RCT
Romestaing 1997 Examined boost versus no boost
Sanguineti 2001 Was a chemotherapy trial
Shelley 2000 Not RCT
Svoboda 1992 Not RCT
Turesson 1984 Not RCT
van Tienhoven 1991 Not RCT
Veronesi 2001 Not RCT
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(Continued)
Vicini 1997 Not RCT
Vicini 2001 Not RCT
Vrieling 2000 Examined boost versus no boost
Wallgren 1978 Investigates preoperative radiation therapy
Wazer 2002 Not RCT
Yamada 1999 Not RCT
Yarnold 1991 Not RCT
Characteristics of ongoing studies [ordered by study ID]
Wallace 1993
Trial name or title WMOA (West Midlands Oncolgy Association Trial)
Methods
Participants Women attending Queen Elizabeth Hospital Birmingham for postoperative radiation following lumpectomy
for carcinoma of the breast
Interventions Experimental (n=31): 40 Gy in 15 fractions plus boost 10-14 MeV of 15 Gy in 5 fractions. Conventional
(n=32): 50 Gy in 25 fractions plus boost as above
Outcomes
Starting date
Contact information
Notes This represents a cohort of a larger trial - more details have been requested
Yarnold 1999
Trial name or title Standardisation of breast radiotherapy (START) trial
Methods
Participants 1. Patients must be 18 years and above, have operable unilateral breast cancer (T1-3, NO-1, MO at presen-
tation)
2. There must be histological confirmation of invasive carcinoma and complete macroscopic excision of
tumour by breast conserving surgery or mastectomy
3. The patient must consent to be part of the study and be available for follow up
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Yarnold 1999 (Continued)
Interventions Radiotherapy schedules using fraction sizes larger than 2.0 Gy
Outcomes In this study several endpoints are being investigated (tumour recurrence, normal tissue effect, quality of life)
. It is intended that each will be analysed separately. If there is discordance between the endpoints in terms
of treatment outcome this will allow discussion of clinical trade-offs. In a subset of patients there will be a
detailed assessment of quality of life. Health economic consequences will also be determined
Starting date 01/01/1999
Contact information clinical.trial@headoffice.mrc.ac.uk
Notes http://www.controlled-trials.com/ISRCTN59368779/
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D A T A A N D A N A L Y S E S
Comparison 1. Unconventional fractionation versus conventional fractionation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Deaths at 5 years 2 2644 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.78, 1.19]
2 Late radiation toxicity at 5 years
- sub-cutaneous tissue
2 1558 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.78, 1.28]
Analysis 1.1. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 1
Deaths at 5 years.
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 1 Deaths at 5 years
Study or subgroup Unconventional Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Owen 2006 146/940 74/470 65.7 % 0.99 [ 0.76, 1.28 ]
Whelan 2002 48/622 51/612 34.3 % 0.93 [ 0.63, 1.35 ]
Total (95% CI) 1562 1082 100.0 % 0.97 [ 0.78, 1.19 ]
Total events: 194 (Unconventional), 125 (Conventional)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
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Analysis 1.2. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 2
Late radiation toxicity at 5 years - sub-cutaneous tissue.
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 2 Late radiation toxicity at 5 years - sub-cutaneous tissue
Study or subgroup Unconventional Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Owen 2006 121/535 56/271 73.9 % 1.09 [ 0.83, 1.45 ]
Whelan 2002 20/394 25/358 26.1 % 0.73 [ 0.41, 1.29 ]
Total (95% CI) 929 629 100.0 % 1.00 [ 0.78, 1.28 ]
Total events: 141 (Unconventional), 81 (Conventional)
Heterogeneity: Chi2 = 1.60, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.01 (P = 0.99)
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
A D D I T I O N A L T A B L E S
Table 1. RTOG/EORTC late radiation morbidity scale
Score Definition
0 No toxicity
1 Slight toxicity
2 Moderate toxicity
3 Marked toxicity
4 Severe toxicity
Table 2. Induration of treated breast (four point scale used in Owen 2006)
Score Definition
0 None
1 Mild
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Table 2. Induration of treated breast (four point scale used in Owen 2006) (Continued)
2 Moderate
3 Marked
Table 3. EORTC Cosmetic Rating System
Global cosmetic
0 = no difference of excellent
1 = small difference or good
2 = moderate difference or fair
3 = large difference or poor
Table 4. Four-point scale used to report breast cosmesis in Owen 2006
Breast Cosmesis
Excellent
Good
Fair
Poor
Table 5. Local recurrences reported in Owen 2006
Trial arms Relapses/ person yrs
Experimental: 42.9 Gy in 13 fractions 42/ 3840
Experimental: 39 Gy in 13 fractions 66/3890
Control: 50 Gy in 25 fractions 50/3965
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Table 6. Conversion of altered fractionation regime to BED
Gray BED (Alpha/beta=4)
42.9 Gy/1/6# 70.72
49 Gy/13# 95.17
42.9 Gy/13# 78.29
50 Gy/25# 75
A P P E N D I C E S
Appendix 1. Search strategy - MEDLINE (Ovid) 1966 to October 2006
1 breast neoplasms/
2 (breast cancer or breast adenocarcinoma).ti.
3 1 or 2
4 rt.fs.
5 radiotherapy dosage/
6 dose response relationship, radiation/
7 Dose Fractionation/
8 radiotherapy/
9 radiotherapy adjuvant/
10 exp radiotherapy, computer assisted/
11 or/4-10
12 (letter or news).pt.
13 (systematic$ adj3 (review$ or overview)).mp.
14 meta-analysis/ or meta-analysis.pt.
15 13 or 14
16 3 and 11 and 15
17 16 not 12
18 randomized controlled trials/ or randomized controlled trial.pt.
19 randomization/ or double blind method/ or single blind method/
20 18 or 19
21 3 and 11 and 20
22 21 not 12
23 22 not 17
24 (breast cancer or breast neoplasm$ or breast adenocarcinoma).ti,ab.
25 (radiotherapy or radiation therapy).ti,ab.
26 (dose or dosage or fraction$).mp.
27 24 and 25 and 26
28 20 and 27
29 28 not 23
30 23 or 29
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31 17 or 30
Appendix 2. Search strategy - EMBASE (Ovid) 1980 to June 2006
1 breast cancer/ or breast adenocarcinoma/ or breast carcinoma/
2 (breast cancer or breast adenocarcinoma).ti.
3 1 or 2
4 Randomized Controlled Trial/
5 RANDOMIZATION/
6 Double Blind Procedure/
7 Single Blind Procedure/
8 or/4-7
9 3 and 8
10 radiotherapy/
11 radiation response/
12 radiation dose fractionation/
13 radiation dose/
14 radiation depth dose/
15 computer assisted radiotherapy/
16 rt.fs.
17 or/10-16
18 17 and 9
19 (breast cancer or breast neoplasm$ or breast adenocarcinoma).tw.
20 (radiotherapy or radiation).tw.
21 (dose or doses or dosage or fraction$).tw.
22 and/19-21
23 9 and 22
24 18 or 23
25 letter/
26 24 not 25
27 meta-analysis/
28 (meta-analy$ or metaanaly$).mp.
29 (systematic$ adj3 (review$ or overview)).mp.
30 or/27-29
31 22 and 30
32 3 and 17 and 30
33 31 or 32
WH A T ’ S N E W
Last assessed as up-to-date: 22 April 2006.
Date Event Description
11 April 2008 Amended Converted to new review format.
23Fraction size in radiation treatment for breast conservation in early breast cancer (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
H I S T O R Y
Protocol first published: Issue 4, 2002
Review first published: Issue 3, 2008
C O N T R I B U T I O N S O F A U T H O R S
The protocol was co-authored by Melissa James, Margot Lehman, Brigid Hickey, Phil Hider, Mark Jeffery.
Melissa James was involved in conceiving and designing the review, screening search results, organising paper retrieval, screening papers
against inclusion criteria, appraising quality of papers, writing to authors, screening data on unpublished studies, providing a clinical
perspective, and writing the review.
Brigid Hickey was involved in conceiving and designing the review, screening papers against inclusion criteria, appraising the quality
of papers, extracting data, analysing data, providing a clinical perspective, writing the review, providing general advice, and securing
funding for the review.
Margot Lehman was involved in screening papers against inclusion criteria, appraising quality of papers, securing funding, extracting
data, providing a clinical perspective and providing advice regarding the review, and securing funding for the review.
Phil Hider was involved in designing the review, doing the search, providing methodological perspective, writing the review, and
providing general advice regarding the review.
Mark Jeffery was involved in designing the review, coordinating the review, screening search results, organising paper retrieval, screening
papers against inclusion criteria, appraising quality of papers, writing to authors, obtaining data on unpublished studies, providing
clinical perspective, and writing the review.
Daniel Francis was involved in coordinating the review, doing the search, screening search results, organising paper retrieval, screening
against inclusion criteria, writing to authors, providing methodological perspective, writing the review, and providing general advice.
D E C L A R A T I O N S O F I N T E R E S T
None known
S O U R C E S O F S U P P O R T
Internal sources
• Princess Alexandra Hospital Cancer Collaborative Group, Australia.
External sources
• No sources of support supplied
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Women with T3 tumours (that is tumour size greater than 5 cm) were eligible for the Owen study (Owen 2006). They comprised
1.6% (22/1410) of the women studied and only 0.83% of the women studied in the review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Breast Neoplasms [∗radiotherapy; surgery]; Combined Modality Therapy [methods]; Dose Fractionation; Mastectomy, Segmental;
Randomized Controlled Trials as Topic
MeSH check words
Female; Humans
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